MARLBOROUGH, Mass.,
May 4, 2016 /PRNewswire/ -- RXi
Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi
company developing innovative therapeutics in dermatology and
ophthalmology that address significant unmet medical needs,
announced today that it will present new data from the Company's
consumer health development program, based on its proprietary
self-delivering RNAi (sd-rxRNA®) technology, at the Society for
Investigative Dermatology (SID) 75th Annual
Meeting. The SID mission is to advance and promote the
sciences relevant to skin health and disease through education,
advocacy and scholarly exchange of scientific information. This
annual meeting is being held May 11-14,
2016 at the Westin Kierland Resort & Spa in Scottsdale, Arizona.
Logo -
http://photos.prnewswire.com/prnh/20130917/NE80755LOGO
RXi's consumer health compounds are intended to affect the
appearance of the skin. As a consumer health product, no
preventative or therapeutic claims can be made. However,
these compounds may be developed more rapidly than therapeutics
and, therefore, the path to the market may be shorter and less
expensive.
On Thursday, May 12, 2016, from
10:00 a.m. to 12:00 p.m. MST, data
will be presented on the Company's ongoing work with its sd-rxRNA®
compounds that target tyrosinase (TYR), a key enzyme in the
synthesis of melanin. RXI-231 is in development as a cosmetic
ingredient that may improve the appearance of uneven skin tone and
pigmentation. These data may be viewed on Poster 651 entitled,
"Self-delivering RNAi compounds for Reduction of
Hyperpigmentation," during the Pigmentation and Melanoma
session.
On Saturday, May 14, 2016, from
10:00 a.m. to 12:00 p.m. MST, data
will be presented on the Company's ongoing work with its sd-rxRNA®
compounds that target collagenase (MMP1), a key enzyme involved in
the breakdown of the extracellular matrix. RXI-185 is in
development as a cosmetic ingredient that may improve the
appearance of wrinkles or skin laxity. These data may be viewed on
Poster 582 entitled, "Potent Self-delivering RNAi Compounds
Targeting MMP1 Reduce UVR Induced MMP1 Upregulation," during the
Photobiology session.
The Company has selected collagenase and tyrosinase as targets
for our self-delivering RNAi platform because they are relevant for
both consumer health and therapeutic development. The Company has
identified additional sd-rxRNA compounds like RXI-231 (TYR) and
RXI-185 (MMP1) that are available to move forward on a separate
therapeutic development path. For example, selected reduction
of MMP1 may be beneficial in the treatment of arthritis, corneal
erosions, endometriosis and possible cancer metastasis. The
inhibition of tyrosinase can play a key role in the management of
diseases such as cutaneous hyperpigmentation disorders and possibly
melanoma.
Both posters will be available under the "Investors –
Presentations & Posters" section of the Company's
website, www.rxipharma.com approximately 1 hour following
each presentation.
About RXi's Proprietary Self-delivering RNAi (sd-rxRNA®)
Platform
Building on the pioneering work of Dr. Craig Mello, Nobel Laureate and RXi's Scientific
Advisory Board Chairman, scientists at RXi developed novel sd-rxRNA
compounds where drug-like properties are built into the RNAi
compound itself. These proprietary compounds are novel RNAi
compounds with enhanced properties for therapeutic use
including: efficient spontaneous cellular uptake, stability,
reduced potential for immune stimulation, and potent, long-lasting
intracellular activity. All cell types tested (primary,
neuronal and non-adherent) internalize sd-rxRNA compounds uniformly
and efficiently, resulting in potent and long lasting
silencing. Efficient cellular uptake is observed both in
vitro and in vivo, including into tissues such as skin
and retina following local administration, and liver following
systemic delivery. RXI-109, an sd-rxRNA compound is designed
to silence connective tissue growth factor (CTGF), which plays a
key role in tissue regeneration and repair. RXI-109 is currently
being evaluated in two clinical trials. A Phase 1/2 clinical
study, RXI-109-1501, is underway to evaluate the safety and
clinical activity of RXI-109 to prevent the progression of retinal
scarring, a harmful component of numerous retinal diseases. In
addition, a Phase 2 clinical trial, RXI-109-1402, is currently
evaluating RXI-109 as a treatment to reduce the recurrence of
hypertrophic scars following scar revision surgery. Over 100
subjects have been treated with RXI-109 by intradermal injection in
all trials to date. Multiple intradermal injections were well
tolerated at all dose levels. RXI-109 was shown to cause a
dose-dependent silencing of CTGF messenger RNA and protein levels
in the treated areas of the skin compared to placebo and
preliminary results from Phase 2a studies indicate a clinical
effect on scar appearance.
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a
clinical-stage RNAi company developing innovative therapeutics in
dermatology and ophthalmology that address significant unmet
medical needs. Building on the pioneering work of RXi's
Scientific Advisory Board Chairman and Nobel Laureate Dr.
Craig Mello, our discovery and
clinical development programs are based on our proprietary RNAi
(sd-rxRNA) platform and Samcyprone™, a topical immunomodulator. Our
clinical development programs include RXI-109, an sd-rxRNA, for the
treatment of dermal and ocular scarring, and Samcyprone™ for the
treatment of such disorders as warts, alopecia areata,
non-malignant skin tumors and cutaneous metastases of
melanoma. RXi's robust pipeline, coupled with an extensive
patent portfolio, provides for multiple product and business
development opportunities across a broad spectrum of therapeutic
areas. We are committed to being a partner of choice for academia,
small companies, and large multinationals. We welcome ideas and
proposals for strategic alliances, including in- and out-licensing
opportunities, to advance and further develop strategic areas of
interest. Additional information may be found on the Company's
website, www.rxipharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such statements include, but are not limited to, statements
about: our ability to successfully develop RXI-109, Samcyprone™ and
our other product candidates (collectively "our product
candidates"); the future success of our clinical trials with our
product candidates; the timing for the commencement and completion
of clinical trials; our ability to enter into strategic
partnerships and the future success of these strategic
partnerships; and our ability to deploy our sd-rxRNA® technology
through partnerships, as well as the prospects of these
partnerships to provide positive returns. Forward-looking
statements about expectations and development plans of RXi's
product candidates and partnerships involve significant risks and
uncertainties, including the following: risks that we may not be
able to successfully develop and commercialize our product
candidates; risks that product development and clinical studies may
be delayed, not proceed as planned and/or be subject to significant
cost over-runs; risks related to the development and
commercialization of products by competitors; risks related to our
ability to control the timing and terms of collaborations with
third parties; and risks that other companies or organizations may
assert patent rights preventing us from developing or
commercializing our product candidates. Additional risks are
detailed in our most recent Annual Report on Form 10-K and
subsequent Quarterly Reports on Form 10-Q under the caption "Risk
Factors." Readers are urged to review these risk factors and
to not act in reliance on any forward-looking statements, as actual
results may differ from those contemplated by our forward-looking
statements. RXi does not undertake to update forward-looking
statements to reflect a change in its views, events or
circumstances that occur after the date of this release.
Contact
RXi Pharmaceuticals Corporation
Tamara McGrillen
508-929-3646
tmcgrillen@rxipharma.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/rxi-pharmaceuticals-to-present-an-update-on-its-consumer-health-programs-at-the-society-for-investigative-dermatology-75th-annual-meeting-300262485.html
SOURCE RXi Pharmaceuticals Corporation